Novavax has been one of several companies developing a potential coronavirus vaccine to block COVID-19. File Photo by Jim Lo Scalzo/EPA-EFE
Dec. 28 (UPI) -- Novavax announced Monday that it's moved to a Phase 3 clinical trial in the United States for its potential COVID-19 vaccine.
The company said it's looking for 30,000 volunteers in the United States and Mexico for the late-stage trial for the NVX-CoV2373 vaccine candidate.
The trial will "evaluate the efficacy, safety and immunogenicity" of the vaccine, it said.
"With the COVID-19 pandemic raging around the globe, this trial is a critical step in building the global portfolio of safe and effective vaccines to protect the world's population," Novavax CEO Stanley Erck said in a statement.
"We are grateful for the hard work and assistance from Operation Warp Speed, the U.S. FDA and the government of Mexico on this program."
Novavax has been one of a number of companies developing a coronavirus vaccine. Two messenger RNA vaccines from Pfizer-BioNTech and Moderna have already been approved for use in the United States and are presently being distributed.
"The launch of this study -- the fifth investigational COVID-19 vaccine candidate to be tested in a Phase 3 trial in the United States -- demonstrates our resolve to end the pandemic through development of multiple safe and effective vaccines," said Dr. Anthony Fauci, the top U.S. infectious diseases expert.
Novavax has already begun a third-stage trial in Britain. Its move to the third phase in the United States was delayed by manufacturing problems.
President Donald Trump takes off his face mask
as he returns to the White House after undergoing treatment for COVID-19 at the Walter Reed National Military Medical Center on October 5. Photo by Ken Cedeno/UPI | License Photo